-
Breakthrough drug for chronic graft anti-host disease (cGVHD)! ROCK2 inhibitor belumosudil U.S. entry review: total mitigation rate > 70%
Time of Update: 2020-12-20
December 04, 2020 // -- Kadmon Holdings recently announced that the U.S. Food and Drug Administration (FDA) has accepted a new drug application (NDA) from Belumosudil (KD025), an oral selective Rho-associated coil protein kinase 2 (ROCK2) inhibitor used to treat patients with chronic graft anti-host disease (cGVHD).
-
Plos One: Kidney disease predicts the risk of hospitalization for COVID-19
Time of Update: 2020-12-20
(Photo: www.pixabay.com) "Previous studies have identified a variety of health conditions associated with an increased risk of COVID hospitalization, including diabetes, heart failure, high blood pressure and chronic kidney disease.
-
Sci Rep: The immunological mechanism by which psoriasis occurs
Time of Update: 2020-12-20
Sugiura explains: "NET and neugenic granulocytes can induce inflammation through a variety of mechanisms; we aim to clarify the role of NET signaling and possibly prevent the occurrence of severe psoriasis-like lesions.
-
Cell Rep: Study reveals therapeutic targets for malignant lung cancer
Time of Update: 2020-12-20
in a recent study, Scientists at Memorial Sloan Kettering reported new findings about a particularly aggressive substum of lung adenocarcinoma, driven by two mutations that often occur simultaneously, called KEAP1 and STK11.
-
New medicine for nose python! The FDA has approved Roche Xolair's new adaptive disorder, Target Blocking IgE to shrink nasal diphernx and improve symptoms
Time of Update: 2020-12-19
December 05, 2020 // -- Roche recently announced that the U.S. Food and Drug Administration (FDA) has approved the anti-inflammatory drug Xolair (Chinese brand name : Umalizumab, generic name: omalizumab, otoxymetin) A new adaptive disorder, as an additional (add-on) maintenance therapy, used to treat adult patients with nasal polyps who do not respond well to nasal corticosteroids (≥18 years old).
-
Hereditary angioedema (HAE) the first oral therapy! FDA approves plasma kinetic peptide release enzyme inhibitor Orladeyo (berotralstat)!
Time of Update: 2020-12-19
it's worth noting that Orladeyo is the first targeted oral therapy approved to prevent HAE seizures, and its approval will make significant progress in the treatment of HAE patients and help reduce the burden of treatment for patients.
-
NEJM: Outbreak investigation reveals potential for human-to-human transmission of the Andean virus
Time of Update: 2020-12-19
the study, high viral loads in large-scale social activities and infected individuals contributed to human-to-human transmission of the Andean virus during outbreaks.
based on these comprehensive data, the authors confirm the need to study the emergence, super-transmission, human-to-human transmission and pathological patterns of the Andean virus in order to improve public health response strategies.
-
Sci Adv: New discoveries by Chinese scientists! A special host protein phosphatase may limit the congenital immune signals of its body!
Time of Update: 2020-12-19
photo source: Dr.DENG Hongyu's group Researchers have previously found that ORF33, a conservative shell protein for herpes virus, is important for the assembly of the γ herpes virus, however, it is not clear whether ORF33 can be used to In this study, researchers first constructed the missing KSHV mutant orF33, which showed that ORF33 inhibited the host's congenital immune response by affecting the functions of the bridging proteins STING and MAVS.
-
Nat Immunol: Heavy! Enhance the therapeutic benefits of immunotherapy by reprogramming T-cells into stem cell-like memory cells!
Time of Update: 2020-12-19
The reprogramming process involves a new method developed by researchers that inhibits the activity of a protein called MEK1/2, which is currently used to effectively treat melanoma, but this study shows that MEK inhibitors do not target specific types of cancer cells, but can widely reprogram T cells to look for multiple types of cancer.
-
Gene and Devel: New Discoveries! The body's biological clock may induce the regeneration β of pancreas and cells!
Time of Update: 2020-12-19
Through a study of diabetic mice, scientists from institutions such as the University of Geneva in Switzerland recently found that the regeneration mechanism of pancreas β cells may be affected by circadian rhythm clocks, which cycle and regulate the body's metabolic function based on the 24 hours of circadian rotation, and that the researchers identified a key role of the core clock component BMAL1 in the process, according to research published in the international journal Gene.
-
Sci Transl Med: What's new! The body's stress hormones may promote sleeping cancer cells to wake up and cause the cancer to return!
Time of Update: 2020-12-19
December 5, 2020 // -- In a recent study published in the international journal Science Translational Medicine, scientists from the United States, Germany and other countries jointly found that natural stress hormones may reactivate dormant cancer cells in mice, and that the results may help develop new treatments for cancer.
-
Gastroenterology: New gene therapy may be expected to target the spread of acting bowel cancer and kill cancer cells
Time of Update: 2020-12-19
6, 2020 // -- In a recent study published in the international journal Gastroenterology, scientists from the South Australian Institute of Health and Medical Research and others analyzed whether gene
-
Hechuan team new results! The successful mapping of key 5hmC biomarkers promises to improve the diagnosis of cancer in humans
Time of Update: 2020-12-19
Photo Source: CC0 Public Domain researcher Professor Chuan He says previous studies have shown that 5hmC may be an excellent biomarker for diagnosis and prognostic assessment of a variety of human diseases, including cancer, but the lack of a map of whole-body tissue may limit our overall understanding of the marker and its potential tissue specificity.
-
Nat Microbiol: An oral drug used to treat influenza virus infection, Molnupiravir, may be effective in blocking the spread of SARS-CoV-2
Time of Update: 2020-12-19
5, 2020 // -- In a recent study published in the international journal Nature Microbiology, scientists from Georgia State University and others found that a new antiviral drug called Mmolnupiravir (MK
-
Sci Transl Med: Scientists have found that amino acid targets associated with the development of non-alcoholic fatty liver disease are expected to help develop new therapies
Time of Update: 2020-12-19
6, 2020 // -- A recent article in the international magazine Science Translational Medicine entitled "Glycine-treatment ameliorates NAFLD by modul fattatingy acid oxidation, In a study by Glutathione
-
PLoS Med: The Mediterranean diet may reduce the risk of relapse in heart disease patients
Time of Update: 2020-12-19
In a recent study published in the international journal PLoS Medicine, scientists from the University of Cordois and others compared the effects of two different healthy eating methods on the endotrial tissue of the body's arterial walls.
-
PNAS: Engineered T cells can be used to treat autoimmune diseases
Time of Update: 2020-12-19
December 5, 2020 // -- A new study finds that new T-cells genetically engineered by health science researchers at the University of Arizona can target and attack pathogenic T-cells that cause type 1 diabetes, which could lead to new immunotherapy.
-
Anti-transplant new drugs! Novartis JAK inhibitor Jakavi treats steroid incurable chronic graft anti-host disease (GvHD) Phase 3 clinical success!
Time of Update: 2020-12-19
data show that oral JAK1/2 inhibitor Jakavi (ruxolitinib, Rusotinib) significantly improved a range of efficacy indicators in patients with steroid incurable/dependent chronic GvHD, including failure-free survival (FFS) and symptoms reported by patients, compared to best available therapies (BAT).
-
Clin Cancer Res: A combination of drug therapies is effective in treating melanoma
Time of Update: 2020-12-19
lead author Amanda Truong of HCI McMahon Labs explains that genetic variants of GNAQ and GNA11 are often found in patients with vine melanoma, the main targets of these drugs.
-
eLife: In-depth disclosure of the function of primary fibre on the inner walls of blood vessels may help develop new diabetes therapies
Time of Update: 2020-12-18
8, 2020 // -- In a recent study published in the international journal eLife, scientists from the Caroline Institute in Sweden and other institutions found that primary fibre (primary cilia, the protr
